

CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, November 24, 2025

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

Pharma Mar, S.A. announces that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as a maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC), with no central nervous system (CNS) metastases whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.

The decision marks the first combination therapy approval in an European country for first-line maintenance treatment of ES-SCLC, a fast growing and aggressive cancer with limited treatment options.

Please find attached press release that Pharma Mar, S.A. will distribute to the media.

Swiss medical authority approves PharmaMar's Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) combination as first-line maintenance therapy for extensive-stage small cell lung cancer




- This is the first approval in Europe for lurbinectedin in this indication.

Madrid, November 24th, 2025. PharmaMar (MSE:PHM) has announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as a maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC), with no central nervous system (CNS) metastases whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide. The decision marks the first combination therapy approval in an European country for first-line maintenance treatment of ES-SCLC, a fast growing and aggressive cancer with limited treatment options.

The Swissmedic approval is based on results from the Phase 3 IMforteⁱ trial, which showed that the lurbinectedin and atezolizumab combination reduced the risk of disease progression or death by 46% and the risk of death by 27%, compared to atezolizumab maintenance therapy alone. Following four cycles of induction therapy, from the point of randomization the median overall survival (OS) for the combination regimen was 13.2 months versus 10.6 months and median progression-free survival (PFS) by independent assessment was 5.4 months versus 2.1 months, respectively. Safety was consistent with the known safety profiles of both treatments

In 2023, Swissmedic granted Temporary Authorisation for the commercialization of lurbinectedin alone for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy without CNS metastases in second line.

Luis Mora, Managing Director of PharmaMar, said: "Switzerland has become the first European country to approve this combination for use as a first-line treatment, giving patients access to this new therapy. We will continue working to ensure that as many patients as possible have access to this new therapy across as many countries as possible."



In October, the U.S Food and Drug Administration (FDA) granted approval for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as a maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC). In addition, the National Comprehensive Cancer Network® (NCCN®) recently updated the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®) for SCLC to include the combination as a preferred regimen for maintenance.

PharmaMar has also submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA), which is currently under review.

SCLC represents about 15% of all lung cancer cases in Europe, each year, approximately 72,600 new cases of SCLC are reported in Europe. Most of these patients are diagnosed with extensive stage disease, which is aggressive and often difficult to treat, with poor prognosis^{ii, iii}.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin, ecubectedin, PM534 and PM54. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com

About Zepzelca®

Zepzelca® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinascidia turbinata in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Tecentriq (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.

Media Contact:

Lara Vadillo – Communications director lvadillo@pharmamar.com

Miriam Collados Gordo – Corporate Communications Manager mcollados@pharmamar.com

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno – VP Capital Markets & Investor Relations

Natalia Amo – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at www.pharmamar.com

i Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial - *The Lancet*

ii Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021). Small-cell lung cancer. *Nature Reviews Disease Primers*, 7(1). <https://doi.org/10.1038/s41572-020-00235-0>

iii Cancer today. (s. f.). <https://gco.iarc.who.int/today/en/fact-sheets-populations#regions>

